Sign In
NewsRadar

AVONTEC GmbH

AVONTEC GmbH is a biopharmaceutical company engaged in the development of a novel class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors, are all directed against biologically validated targets in major chronic diseases with high unmet medical need. AVONTEC focuses its patented technology on chronic inflammatory diseases of the respiratory system, skin and joints.

• Show past press releases
• Edit this company

Elevator Pitch
Avontec addresses a new target and thus introduces a novel antiinflammatory principle with a complete new drug class and delivery technology. pursues a virtual business model concentrating all activities on product development.

Contact Information
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
Fraunhoferstrasse 15
Muenchen 82152
Germany
+49 (0)89 8565 1600
+49 (0)89 8565 1620
http://www.avontec.com
Dr. Thomas Schulze
+49 (0)89 8565 1600

Company Facts
Founded:Dec 2001
Founders:Gerd Hasenfuß, Markus Hecker
CEO:Thomas Schulze
CTO or technical lead:Wolfgang Barth
CFO or finance director:Thomas Niederfeld
Head of Sales:
Head of Marketing:

Stage:Startup
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:Pre-revenue
Funding raised:Yes
Funding sought:No
Seeking Partnerships:No

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,807
Tech investments
From our Online Data Service
17,301
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Mar 23€2.0MInternet services
Mar 23€1.5MInternet services
Mar 23€110.0MInternet commerce
Mar 21€1.9MBusiness applications
Mar 20€1.0MInternet commerce
Mar 20€12.0ME-Commerce

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.